MCI-062

**MCI-062** is a novel, potent, and selective small molecule **pan-RAS inhibitor** developed at the Drug Discovery Research Center at the Mitchell Cancer Institute. It directly interacts with RAS proteins to inhibit GTP binding and thus blocks RAS-effector signaling, including in KRAS-mutant cancers. MCI-062 is characterized by its ability to inhibit growth and induce apoptosis in tumor cells harboring activations or mutations in RAS isoforms (KRAS, NRAS, HRAS), making it potentially useful for various RAS-driven cancers, including lung, colorectal, and pancreatic cancers. MCI-062 functions in an isoform-independent manner, distinguishing it from mutation-specific inhibitors. It has shown potent activity (less than 10 nM potency in cellular assays) in preclinical studies and is under investigation for its synergy with immunotherapy approaches[6][10][13][1][4][2][8][12][14].

Other names

MCI-062MCI062MCI 062ANC 007ANC007ANC-007